In this issue:
Australian radical prostatectomy and pelvic lymphadenectomy rates
Clinical outcomes in different ethnic groups with mCRPC
Percent free PSA predicts outcomes after biochemical recurrence
Willingness to trade-off risks and benefits of prostate cancer treatments
Cancers associated with BRCA1 and BRCA2 pathogenic variants
Enhanced recovery and prehabilitation pathways for RARP
Prostate cancer upgrading with serial MRI and repeat biopsy during AS
Nomogram to identify candidates for AS
Testosterone replacement therapy after radical prostatectomy
Please login below to download this issue (PDF)